аллергический ринитантигистаминные препаратыастмакрапивница1.Bousquet J., Van Cauwenberge P., Khaltaev N. et al. Allergic rhinitis and its impact on asthma in collaboration with the World Health Organization. J. Allergy Clin. Immunol. 2001, v. 108 (Suppl. 5), p. 147-334.2.Brozek J.L., Baena-Cagnani C.E., Bonini S. et al. Methodology for development the Allergic Rhinitis and its Impact of Asthma Guideline 2008 update Allergy. 2008, v. 63 (1), p. 38-46.3.Canonica G.W. et al. Efficacy of Desloratodin in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 2007, v. 62, p. 359-366.4.Asher M.I.,Montefort S. Bjorksten B. et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Hhases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006, v. 368, p. 733-744.5.Grize L.,Gassner M., Wuthrich B. et al. Trends in prevalence of asthma,allergic rhinitis and atopic dermatitis in 5-7 year old Swiss children from 1992 to 2001. Allergy. 2006, v. 61, p. 556-562.6.Гущин И.С., Ильина Н.И., Польнер С.А. Аллергический ринит. Пособие для врачей. ГНЦ «Институт иммуноло- гии» МЗ РФ, РААКИ, М., 2002, 68 с. 7. Клиническая аллергология. Руководство для практичес- ких врачей. Под редакцией акад. РАМН, проф. Хаитова Р.М. М., «Медпресс-информ». 2002, 623 с.7.Лусс Л.В. Этиология, патогенез, проблемы диагностики и лечения аллергического ринита. РМЖ. 2003, т. 11, с. 718-729.8.Strachan D., Sibbald B., Weiland S. et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol. 1997, v. 8, p. 161-176.9.Marinho S., Simpson A., Lowe L. et al. Rhinoconjunctivitis in 5-year-old children: a population-based birth cohort study Allergy. 2007, v. 62 (4), p. 385-393.10.Magnan A., Meunier J.P., Saugnac C. et al. Frequency and impact of allergic rhinitis in asthma patients in everyday general medical practice: a French observational cross-sectional study. Allergy. 2007, Nov 20. 12. van Oene C.M., van Reij E.J.F. Spranges M.A.G., Fokknes11.W.J. Quality-assesment of disease-specific quality of life questionnaires for rhinitis and rhinosinusitis: a systematic review Allergy. 2007, v. 62, p. 1359-1371.12.Spector S. L., Nicklas R.A., Chapman J.A. et al. Symptom severity assessment of allergic rhinitis: part 1. Ann Allergy Asthma Immunol. 2003, Aug., v. 91 (2), p. 105-114.13.Pop C.F., Chereches-Panta P., Nanulescu M.V. Quality of life in children with bronchial asthma and allergic rhinitis. Pneumologia. 2006, Apr-Jun., v. 55 (2), p. 74-79.14.Ciprandi G., Cirillo I., Pistorio A. Impact of allergic rhinitis on asthma: effects on spirometric parameters. Allergy. 2007, Oct., p. 18.15.Lasmar L.M., Camargos P.A., Ordones A.B. et al. Prevalence of allergic rhinitis and its impact on the use of emergency care services in a group of children and adolescents with moderate to severe persistent asthma. J. Pediatr. (Rio J). 2007, Nov-Dec., v. 83 (6), p. 555-561.16.Hellings P.W., Fokkens W. Allergic rhinitis and its impact on otorhinolaringology. 2006, v. 61, p. 656-664.17.Reichmuth D., Lockey R.F. Present and potential therapy for allergic rhinitis. BioDrugs. 2000, v. 14, p. 371-387. 19. Executive Summary Report of the American Academy of Allergy, Asthma, and Immunology Task Force on Allergic Disorders: Promoting Best Practice. Raising the standard of care for patients with allergic disorders. AAAAI: Milwaukee Nov. 1998. 20. P. van Cauwenberge, Bachert C., Passalacqua G. et al. Position paper. Consensus statement on the treatment of allergic rhinitis. Allergy. 2000, v. 55, p. 116-134.18.Canonica G.W., Bousquet J., Mullol J. et al. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007, v. 62, Suppl. 85, p. 17-25.19.Schatz M. A survey of the burden of allergic rhinitis in the20.USA. Allergy. 2007, v. 62, Suppl. 85, p. 9-16.21.Lamb C.E., Ratner P.H., Johnson C.E. et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med. Res. Opin. 2006, Jun., v. 22 (6), p. 1203-1210. 24. Global Initiative for Asthma/ Global Strategy for Asthma Management and Prevention. Revision. 2006. www.ginasthma.com22.Геппе Н.А. Современные представления о тактике лече- ния бронхиальной астмы у детей. РМЖ. 2002, т. 10, № 7, с. 353-358. 26. Аллергический ринит у детей. Пособие для врачей (под23.ред. А.А. Баранова, Н.А. Геппе, М.Р. Богомильского,24.Б.С. Каганова, В.А. Ревякиной). М., «Медицина», 2002, с. 9-64.25.Fokkens W.,van Drunen C.M. Nose and lung,two of a kind? Allergy. 2006, v. 61, p. 653-655.26.Lundblad L., Allergy. 2002, v. 57, p. 969-971.27.Mosges R., Klimek L. Today's allergic rhinitis patients are different; new factor that may play a role. Allergy. 2007, v. 62, p. 969-975.28.Demoly P., Rullier-Meyer P., Godard P., Bousquet J., Michel29.F.B. Nasal allergy and asthma: one or two diseases? Bull Acad Natl Med. 2005, Oct., v. 189 (7), p. 1461-1473.30.Linneberg A., Henrik Nielsen N., Frolund L. et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002, v. 57, p. 969-971.31.Koga T., Matsuse H., Kohrogi H. et al. Impact of Nasal Condition on Self-assessed Disease Control and Treatment Satisfaction in Patients with Asthma Complicated by Allergic Rhinitis. Allergol Int. 2007, Dec., v. 56 (4), p. 427-431.32.Cruz A.A., Popov T., Pawankar R. et al. ARIA Initiative Scientific Committee.Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy. 2007, v. 62, Suppl 84, p. 1-41.33.Thomas M. Allergic rhinitis: evidence for impact on asthma. BMC Pulm Med. 2006, Nov 30, v. 6 Suppl 1, p. 4. Review.34.Reinartz S.M., Overbeek S.E., Kleinjan A., van Drunen C.M. et al. Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. Allergy. 2005, Oct., v. 60 (10), p. 1301-1307.35.Stephen P. The Impact of Comorbid Atopic Disease on Asthma: Clinical Expression and Treatment. J. of Asthma. 2007, v. 44, p. 149-161.36.Ciprandi G., Cirillo I., Pistorio A. Impact of allergic rhinitis on asthma: effects on spirometric parameters. Allergy. 2007, Oct., p. 18.37.Watelet J.-B,Van Zele T., Gjomarkaj M. et al. Tissue remodelling in upper airways: where is the link lower airway remodelling? Allergy. 2006, v. 61, p. 1249-1258.38.Mosges R., Schmalz P., Koberlein J. et al. The RHINASTHMA-Quality of Life Scale German Adapted Version: validation of a new disease specific quality of life scale for patients suffering from allergic rhinitis and bronchial hyperreactivity HNO. 2007, May, v. 55 (5), p. 357-364.39.Bjerg A., Hedman L., Perzanowski M.S. et al. Family history of asthma and atopy: in-depth analyses of the impact on asthma and wheeze in 7- to 8-year-old children. Pediatrics. 2007, Oct., v. 120 (4), p. 741-748.40.Peters S. The impact of comorbid atopic disease on asthma: clinical expression and treatment. J. Asthma. 2007, Apr., 44 (3), p. 149-61. Review.41.Meltzer E.O. Allergic rhinitis: the impact of discordant perspectives of patient and physician on treatment decisions. Clin Ther. 2007, Jul., v. 29 (7), p. 1428-1440.42.Marple B.F., Fornadley J.A., Patel A.A. et al. American Academy of Otolaryngic Allergy Working Group on Allergic Rhinitis. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg. 2007, Jun., v. 136 (6 Suppl), p. 107-124. 44. Executive Summary of the Workshop Report. Allergy. 2002, v. 57, p. 841-855.43.Demoly P., Rullier-Meyer P., Godard P. et al. Nasal allergy and asthma: one or two diseases? Bull Acad. Natl. Med. 2005,Oct., v. 189 (7), p. 1461-1473.44.Bousquet J., P. van Cauwenberge, N. Ait Khaled et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy. 2006, v. 61 (9), p. 1086-1096.45.ARIA -revision 2007. http://www.whiar.org46.Bachert C., van Cauwenberge P. Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. Clin. Ther. 2007, Sep., v. 29 (9), p. 1795-1802.47.Berger W.E., Schenkel E.J., Mansfield L.E. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann. Allergy Asthma Immunol. 2002, Nov., v. 89 (5), p. 485-491.48.Khanna P., Shah A. Categorization of patients with allergic rhinitis: a comparative profile of «sneezers and runners» and «blockers». Ann. Allergy Asthma Immunol. 2005, Jan., v. 94 (1), p. 60-64.49.Bousquet J., Bindslev-Jensen C., Canonica G.W. et al. The ARIA/ EAACI criteria for antihistamines: An assessment of the efficacy, safety, and pharmacology of desloratadine. Allergy. 2004, v. 59 (suppl 77), p. 4-16.50.pediatric seasonal allergic rhinitis. Allergy Asthma Proc. 2005, Mar-Apr., v. 26 (2), p. 95-102. Review.51.Lehman J.M., Blaiss MS. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs. 2006, v. 66 (18), p. 2309-2319. Review.52.Layton D., Wilton L., Boshier A. et al. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf. 2006, v. 29 (10), p. 897-909.53.Spangler D.L., Brunton S. Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis. South Med. J. 2006, Jun., v. 99 (6), p. 593-599. Review.54.Camelo-Nunes I.C. New antihistamines: a critical view. J. Pediatr (Rio J). 2006, Nov., v. 82 (5 Suppl), p. 173-180. Review.55.Traidl-Hoffmann C., Munster I., Ring J., Behrendt H. Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: Implications for anti-inflammatory activity of antihistamines. Int. Arch. Allergy Immunol. 2006, v. 140 (4), p. 315-320.56.Tworek D., Bochenska-Marciniak M., Kupczyk M. et al. The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis.Pulm Pharmacol Ther. 2007, v. 20 (3), p. 244-249.57.Mullol J., Roca-Ferrer J., Alobid I. et al. Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival. Clin. Exp. Allergy. 2006, Jan., 36 (1), p. 52-58.58.Cyr M.M., Hayes L.M., Crawford L. et al.The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study. Int. Arch. Allergy Immunol. 2005, Nov., v. 138 (3), p. 209-21659.Pradalier A., Neukirch C., Dreyfus I., Devillier P. Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy. 2007, Nov., v. 62 (11), p. 1331-133460.Scharf M., Berkowitz D.Effects of desloratadine and alcohol coadministration on psychomotor performance. Curr. Med. Res. Opin. 2007, Feb., v. 23 (2), p. 313-321.61.L.M. DuBuske Pharmacology of Desloratadine Special Characteristics. Clin. Drug Invest. 2002.62.Srinubabu G., Patel R.S., Shedbalkar V.P. et al. Development and validation of high-throughput liquid chromatography-tandem mass spectrometric method for simultaneous quantification of loratadine and desloratadine in human plasma. J. ChromatogrB Analyt Technol. Biomed. Life Sci. 2007, Dec. 15, v. 860 (2),p. 202-208.63.DuBuske L.M. Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. Expert. Opin. Pharmacother. 2005, Nov., 6 (14), p. 2511-2523. Review64.Keith P.K., Luciuk G. Effectiveness of desloratadine 5 mg once daily in patients with symptoms of seasonal allergic rhinitis: results of a Canadian multicenter, open-label trial. Clin. Ther. 2007, Mar., v. 29 (3), p. 419-426.65.Pradalier A., Neukirch C., Dreyfus I., Devillier P. Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy. 2007, Nov., v. 62 (11), p. 1331-1334.66.Kim K., Sussman G., Hebert J. et al. Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2006, Mar., v. 96 (3), p. 460-465.67.Meltzer E.O., Jalowayski A.A., Vogt K. et al. Effect of desloratadinetherapy on symptom scores and measures of nasalpatency in seasonal allergic rhinitis: results of a single-center,placebo-controlled trial. Ann. Allergy Asthma Immunol. 2006,Feb., v. 96 (2), p. 363-368.68.Astafieva N.G. Effect of Desloratadine on symptom relief in pollen-allergic patients. In Abstr. Book of XXII Annual Congress EAACI. 2003, p. 97469.Reinberg et al. J. Allergy Clin. Immunol. 1988, v. 81, p. 51.70.Schenkel E.J. Effect of desloratadine on the control of morning symptoms in patients with seasonal and perennial allergic rhinitis Allergy Asthma Proc. 2006, v. 27, p. 465-472.71.Meltzer et al. Clin. Drug. Invest. 2001, v. 21, p. 25. Data on file, Schering Corporation.72.Bachert C., Brostoff J., Scadding G.K. et al. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. Allergy. 1998, v. 53, p. 969-975.73.Khanna P., Shah A. Categorization of patients with allergicrhinitis: a comparative profile of «sneezers and runners» and«blockers». Ann. Allergy Asthma Immunol. 2005, Jan., v. 94 (1),p. 60-64.74.Nayak A., Lorber R., Salmun L.M. et al. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2000, v. 105 (1 pt 2), p. 384.75.Schenkel E. et al. Amer. Acad. of Allergy and Clin. Immunol. 2002, Abstr. p. 23276.Bachert C., van Cauwenberge P. Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. Clin. Ther. 2007, Sep., 29 (9), p. 1795-1802.77.Canonica G.W., Tarantini F., Compalati E., Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 2007, Apr., v. 62 (4), 359-366. Review.78.Lam H.C., Tong M.C., Van Hasselt C.A. Rhinitis symptoms and quality of life in patients with chronic perennial rhinitis treated with desloratadine. J. Laryngol Otol. 2007, Dec., v. 121 (12), p. 1151-1155.79.Berger W.E. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf. 2005, v. 28 (12), p. 1101-1018. Review.80.DuBuske L.M. Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. Expert Opin Pharmacother. 2005, Nov., v. 6 (14), p. 2511-2523. Review.81.Bousquet J., Bindslev-Jensen C., Canonica G.W. et al. The ARIA/ EAACI criteria for antihistamines: An assessment of the efficacy, safety, and pharmacology of desloratadine. Allergy. 2004, v. 59 (suppl 77). p. 4-16.82.Gupta S.K., Kantesaria B., Banfield C., Wang Z. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. Br. J. Clin. Pharmacol. 2007, Aug, v. 64 (2), p.174-18483.Gupta S., Khalilieh S., Kantesaria B., Banfield C. Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br. J. Clin. Pharmacol. 2007, May, v. 63 (5), p. 534-540.84.Rossi G.A., Tosca M.A., Passalacqua G.* et al. Evidence of desloratadine syrup efficacy and tolerability in children with pollen induced allergic rhinitis. Allergy. 2005, v. 60, p. 416-417.85.Смирнова Г.И. Новые возможности лечения аллергичес- ких заболеваний у детей с применением дезлоратадина. Вопр. совр. педиатрии. 2004, т. 3, № 3, с. 33-38.86.Prenner B., Kim K., Gupta S. et al. Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. Expert. Opin. Drug Saf. 2006, Mar, v. 5 (2), p. 211-223. Review.87.Hansen J., Klimek L., Hormann K. Pharmacological management of allergic rhinitis in the elderly: safety issues with oral antihistamines. Drugs Aging. 2005, v. 22 (4), p. 289-296. Review88.Raphael G.D., Angello J.T., Wu M.M., Druce H.M. Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 2006, Apr, v. 96 (4), p. 606-614.89.Jutel M., Blaser K., Akdis C.A. Histamine in allergic inflammation and immune modulation. Int. Arch. Allergy Immunol. 2005, v. 137, p. 82-92.90.Academy Position Statement: The Use of Antihistamines in Patients with Asthma November. 2002.91.Wilson A.M. The role of antihistamines in asthma management. Treat. Respir. Med. 2006, v. 5 (3), p. 149-158.92.Youssef H.H. et al. JAMA. 1996, v. 6, p. 37-42.93.Nathan R. Desloratadine relieved nasal congestion in patients with seasonal allergic rhinitis and concurrent asthma. In Abstr. book of the 2000 Annual Meeting of the American College of Allergy, Asthma & Immunology. 2000, Nov. v. 3-8, Seattle, Wa. Abstr. 51.94.Fireman P.J. Therapeutic approaches to allergic rhinitis: treating the child. JACI, 2000, v. 105, p. 16-21.95.Baena-Cagnani C. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy. 2001, v. 56 (suppl. 65), p. 21-27.96.Kupczyk M., Bogacka E., Bochenska-Marciniak M. et al. The effect of desloratadine on use of rescue beta2-agonists and symptoms in patients suffering from seasonal allergic rhinitis and asthmaPol Merkur Lekarski. 2005, Feb, v. 18 (104), p. 129-132.97.Salmun L.M. Antihistamines in late-phase clinical development for allergic disease. Expert Opinion on Investigational Drugs. 2002, v. 11 (2), p. 259-273 (Review).98.Murdoch D., Goa K.L., Keam S.J. Desloratadine: An update of its efficacy in the management of allergic disorders. Drugs. 2003, v. 63 (19), p. 2051-2077. (Review).99.Murdoch D., Goa K.L., Keam S.J. Desloratadine: An update of its efficacy in the management of allergic disorders. Drugs. 2003, v. 63 (19), v. 2051-2077.100.Ratner P. and the Desloratadine Study Group. Desloratadine improved ASTHMA symptoms and reduced bronchodilatator use in 2 studies of patients with asthma and SAR. Ann. Meeting of American College of Allergy, Asthma in4 Immunology, Seattle. 2000.101.Bonini S., Bonini M., Bousquet J. et al. Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN. Allergy. 2006, v. 61, p. 681-692.102.Baena-Cagnani C.E., Berger W.E., DuBuske L.M. et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol. 2003, Apr, v. 130 (4), p. 307-313.103.Reinartz S.M., Overbeek S.E., Kleinjan A. et al. Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients.Allergy. 2005, Oct. v. 60 (10), p. 1301-1307104.Passalacqua G., Canonica G. Treating the allergic patient: think globally, treat globally. Allergy. 202, v. 57, p. 876-883.105.Ciebiada M., Gorska-Ciebiada M., DuBuske L.M., Gorski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis Ann Allergy Asthma Immunol. 2006, Nov. v. 97 (5), p. 664-671.106.Zhao Y., Van Hasselt C.A., Woo K., Wong Y., Leung P. The effect of desloratadine on the TXB2 and leukotrienes levels in the nasal lavage fluid of allergic rhinitis animal model Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2005, Apr. v. 19 (8), p. 365.107.Danov Z., Guilbert T. Prevention of asthma in childhood Current opinion in Allergy and Clinical Immunology. 2007, v. 7 (2), p. 174-179.108.Iikura, Y., Naspitz, C.K., Mikawa H. et al. Prevention of asthma by ketotifen in infants with atopic dermatitis. Ann Allergy. 1992, v. 68, p. 233-236.109.Bustos G.J., Bustos D., Bustos G.J. et al. Prevention of asthma with ketotifen in preasthmatic children: 3 three-year follow-up study. Clin Exp Allergy. 1995, v. 25, p. 568-573110.ETAC Study Group Warner J.O. ACI Int. 2004, v. 16/5, p. 186-191.111.Warner J.O. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months treatment and 18 months posttreatment follow up. J. Allergy Clin. Immunol, 2001, v. 108, p. 929-937.112.Prevention of Allergy and Asthma. ACI Int. 2000, v. 12/6, p. 288-302.113.Bousquet J., Dahl R., Khaltaev N. Global Alliance against Chronic Respiratory Diseases. Allergy. 2007, v. 62, p. 216-223.